N/A
Manufactured by UNICHEM PHARMACEUTICALS (USA), INC.
29,885 FDA adverse event reports analyzed
Last updated: 2026-04-14
SOTALOL HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by UNICHEM PHARMACEUTICALS (USA), INC.. The most commonly reported adverse reactions for SOTALOL HYDROCHLORIDE include ATRIAL FIBRILLATION, DRUG INEFFECTIVE, DYSPNOEA, FATIGUE, DIZZINESS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for SOTALOL HYDROCHLORIDE.
Out of 16,057 classified reports for SOTALOL HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 29,885 FDA FAERS reports that mention SOTALOL HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include ATRIAL FIBRILLATION, DRUG INEFFECTIVE, DYSPNOEA, FATIGUE, DIZZINESS, DIARRHOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list UNICHEM PHARMACEUTICALS (USA), INC. in connection with SOTALOL HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.